130 related articles for article (PubMed ID: 20129130)
1. Population-based differences in treatment outcome following anticancer drug therapies.
Ma BB; Hui EP; Mok TS
Lancet Oncol; 2010 Jan; 11(1):75-84. PubMed ID: 20129130
[TBL] [Abstract][Full Text] [Related]
2. Personalized-medicine trials on the rise.
Benowitz S
J Natl Cancer Inst; 2012 Oct; 104(19):1425-6. PubMed ID: 23008496
[No Abstract] [Full Text] [Related]
3. Personalized cancer therapy with selective kinase inhibitors: an emerging paradigm in medical oncology.
McDermott U; Settleman J
J Clin Oncol; 2009 Nov; 27(33):5650-9. PubMed ID: 19858389
[TBL] [Abstract][Full Text] [Related]
4. Pharmacology, pharmacogenetics, and pharmacoepidemiology: three ps of individualized therapy.
Dawood S
Cancer Invest; 2009 Oct; 27(8):809-15. PubMed ID: 19731103
[No Abstract] [Full Text] [Related]
5. Molecular predictors of response to epidermal growth factor receptor antagonists in non-small-cell lung cancer.
Sequist LV; Bell DW; Lynch TJ; Haber DA
J Clin Oncol; 2007 Feb; 25(5):587-95. PubMed ID: 17290067
[TBL] [Abstract][Full Text] [Related]
6. Gefitinib (Iressa, ZD1839): a novel targeted approach for the treatment of solid tumors.
Von Pawel J
Bull Cancer; 2004 May; 91(5):E70-6. PubMed ID: 15582898
[TBL] [Abstract][Full Text] [Related]
7. The role of the molecular footprint of EGFR in tailoring treatment decisions in NSCLC.
Gately K; O'Flaherty J; Cappuzzo F; Pirker R; Kerr K; O'Byrne K
J Clin Pathol; 2012 Jan; 65(1):1-7. PubMed ID: 22039281
[TBL] [Abstract][Full Text] [Related]
8. [Possibilities and limitations of stratified medicine based on biomarkers and targeted therapies in oncology].
Ludwig WD
Z Evid Fortbild Qual Gesundhwes; 2012; 106(1):11-22. PubMed ID: 22325103
[TBL] [Abstract][Full Text] [Related]
9. Epidermal growth factor receptor: pathway, therapies, and pipeline.
Goffin JR; Zbuk K
Clin Ther; 2013 Sep; 35(9):1282-303. PubMed ID: 24054705
[TBL] [Abstract][Full Text] [Related]
10. Interpreting disparate responses to cancer therapy: the role of human population genetics.
Maitland ML; DiRienzo A; Ratain MJ
J Clin Oncol; 2006 May; 24(14):2151-7. PubMed ID: 16682733
[TBL] [Abstract][Full Text] [Related]
11. [Medical treatment of cancer in the elderly].
Bangerter M; Heinrich B; Brudler O
MMW Fortschr Med; 2004 Sep; 146(40):30-2. PubMed ID: 15529665
[TBL] [Abstract][Full Text] [Related]
12. Developing clinical recommendations for breast, colorectal, and lung cancer adjuvant treatments using the GRADE system: a study from the Programma Ricerca e Innovazione Emilia Romagna Oncology Research Group.
De Palma R; Liberati A; Ciccone G; Bandieri E; Belfiglio M; Ceccarelli M; Leoni M; Longo G; Magrini N; Marangolo M; Roila F;
J Clin Oncol; 2008 Mar; 26(7):1033-9. PubMed ID: 18309939
[TBL] [Abstract][Full Text] [Related]
13. Cancer chemotherapy and cardiovascular risks: is capecitabine-induced hypertriglyceridemia a rare adverse effect?
Seminara P; Losanno T; Emiliani A; Manna G
Cardiology; 2010; 116(1):42-4. PubMed ID: 20431291
[TBL] [Abstract][Full Text] [Related]
14. Ethnic differences in response to epidermal growth factor receptor tyrosine kinase inhibitors.
Calvo E; Baselga J
J Clin Oncol; 2006 May; 24(14):2158-63. PubMed ID: 16682734
[TBL] [Abstract][Full Text] [Related]
15. [Oncology 2010].
Wörmann B
Dtsch Med Wochenschr; 2010 Jun; 135(25-26):1339-40. PubMed ID: 20556695
[No Abstract] [Full Text] [Related]
16. Pharmacogenetics in breast cancer: focus on hormone therapy, taxanes, trastuzumab and bevacizumab.
Longo R; D'Andrea M; Sarmiento R; Gasparini G
Expert Opin Investig Drugs; 2010 Apr; 19 Suppl 1():S41-50. PubMed ID: 20374029
[TBL] [Abstract][Full Text] [Related]
17. Epidermal growth factor receptor tyrosine kinase inhibitors: present and future role in gastrointestinal cancer treatment: a review.
Arnold D; Peinert S; Voigt W; Schmoll HJ
Oncologist; 2006 Jun; 11(6):602-11. PubMed ID: 16794239
[TBL] [Abstract][Full Text] [Related]
18. EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: analysis of data from the phase 3 FLEX study.
Pirker R; Pereira JR; von Pawel J; Krzakowski M; Ramlau R; Park K; de Marinis F; Eberhardt WE; Paz-Ares L; Störkel S; Schumacher KM; von Heydebreck A; Celik I; O'Byrne KJ
Lancet Oncol; 2012 Jan; 13(1):33-42. PubMed ID: 22056021
[TBL] [Abstract][Full Text] [Related]
19. Pharmacogenetics of anticancer drug sensitivity in non-small cell lung cancer.
Danesi R; de Braud F; Fogli S; de Pas TM; Di Paolo A; Curigliano G; Del Tacca M
Pharmacol Rev; 2003 Mar; 55(1):57-103. PubMed ID: 12615954
[TBL] [Abstract][Full Text] [Related]
20. [Analysis of factors affecting clinical cancer chemotherapy].
Wakui A; Taguchi T
Gan No Rinsho; 1983 Aug; 29(10):1199-204. PubMed ID: 6415312
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
